Jonathan Young - 17 Nov 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
17 Nov 2023
Net transactions value
-$440,259
Form type
4
Filing time
21 Nov 2023, 17:30:04 UTC
Previous filing
04 Oct 2023
Next filing
12 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale $440,259 -30,000 -16% $14.68 153,177 17 Nov 2023 Direct F1
holding AKRO Common Stock 20,000 17 Nov 2023 By EA Irrevocable Trust F2
holding AKRO Common Stock 20,000 17 Nov 2023 By CM Irrevocable Trust F2
holding AKRO Common Stock 20,000 17 Nov 2023 By JL Irrevocable Trust F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.50 to $15.038, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
F2 These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.